CEFTAROLINE Drug Patent Profile
✉ Email this page to a colleague
When do Ceftaroline patents expire, and when can generic versions of Ceftaroline launch?
Ceftaroline is a drug marketed by Apotex and is included in one NDA.
The generic ingredient in CEFTAROLINE is ceftaroline fosamil. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ceftaroline fosamil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceftaroline
A generic version of CEFTAROLINE was approved as ceftaroline fosamil by APOTEX on September 21st, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CEFTAROLINE?
- What are the global sales for CEFTAROLINE?
- What is Average Wholesale Price for CEFTAROLINE?
Summary for CEFTAROLINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | CEFTAROLINE at DailyMed |
US Patents and Regulatory Information for CEFTAROLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | CEFTAROLINE FOSAMIL | ceftaroline fosamil | POWDER;INTRAVENOUS | 208075-001 | Sep 21, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Apotex | CEFTAROLINE FOSAMIL | ceftaroline fosamil | POWDER;INTRAVENOUS | 208075-002 | Sep 21, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
